Article
HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial.
Immunogenetics - 1 May 2014
Prentice Heather A, Ehrenberg Philip K, Baldwin Karen M, Geretz Aviva, Andrews Charla, Nitayaphan Sorachai, Rerks-Ngarm Supachai, Kaewkungwal Jaranit, Pitisuttithum Punnee, O'Connell Robert J, Robb Merlin L, Kim Jerome H, Michael Nelson L, Thomas Rasmi
Abstract excerpt
RV144 is the first phase 3 HIV vaccine clinical trial to demonstrate efficacy. This study consisted of more than 8,000 individuals in each arm of the trial, representing the four major regions of Thailand. Human leukocyte antigen (HLA) class I and killer cell immunoglobulin-like receptor (KIR) genes, as well as 96 genome-wide ancestry informative markers (AIMs) were genotyped in 450 placebo HIV-1-uninfected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.